Prescient Therapeutics Ltd
PTX
Company Profile
Business description
Prescient Therapeutics Ltd is conducting clinical studies and other research and development relating to the company's proprietary technologies and products, particularly PTX-100; Business development activities to support the promotion and partnering of Prescient's proprietary technologies and products. The company has single operating segment, being the research and development of oncology therapies. Its technologies are PTX-100, CellPryme, CellPryme-M, CellPryme-A, OmniCAR, etc.
Contact
385 Bourke Street
Suite 2, Level 11
MelbourneVIC3000
AUST: +61 396927222
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
1
Stocks News & Analysis
stocks
An undervalued stock to buy that even Warren Buffett likes
Trading at an 18% discount, this wide-moat stock is a rare find.
stocks
Ahead of an IPO, the maths behind Databrick’s $190 billion valuation doesn’t add up
The data and AI company is one of the world’s strongest private companies, but a PitchBook report says it’s unattractive at the current price.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,860.50 | 14.90 | 0.17% |
| CAC 40 | 8,077.80 | 3.63 | -0.04% |
| DAX 40 | 25,408.64 | 142.11 | 0.56% |
| Dow JONES (US) | 51,828.62 | 478.64 | 0.93% |
| FTSE 100 | 10,695.25 | 15.26 | 0.14% |
| HKSE | 24,666.09 | 156.00 | 0.64% |
| NASDAQ | 27,068.72 | 129.34 | 0.48% |
| Nikkei 225 | 66,327.56 | 36.64 | -0.06% |
| NZX 50 Index | 13,830.68 | 19.57 | 0.14% |
| S&P 500 | 7,743.41 | 39.28 | 0.51% |
| S&P/ASX 200 | 8,690.60 | 25.60 | 0.30% |
| SSE Composite Index | 3,820.82 | 67.55 | -1.74% |